With your own knowledge and the help of the following document:

Document 1 (Title: Recurrent Rectal Cancer Management Following Primary Radiotherapy): Pelvic exenteration represents a potentially curative option for selected patients with recurrent rectal cancer, though previous treatments may influence subsequent surgical outcomes. Multivariate analysis of prognostic factors reveals that primary tumor radiotherapy history significantly impacts post-exenteration prognosis through several documented mechanisms. Retrospective review of 182 patients undergoing pelvic exenteration for recurrent disease demonstrated that prior radiotherapy was independently associated with reduced 5-year survival (hazard ratio 1.78, 95% CI 1.26-2.47) after controlling for other established prognostic variables. Histopathological analysis of exenteration specimens revealed that previously irradiated tumors demonstrated altered recurrence patterns, with increased likelihood of multifocal pelvic disease and perineural invasion compared to radiation-naïve recurrences. Intraoperative assessment consistently documented increased technical difficulty achieving clear margins in previously irradiated fields, with complete resection rates of 72% versus 89% in non-irradiated cases. Additionally, postoperative complication profiles showed significant differences, with prior radiotherapy associated with doubled rates of major wound complications and anastomotic failures. Tissue analysis demonstrated radiation-induced fibrosis and microvascular changes that appear to both complicate surgical procedures and potentially provide microenvironmental conditions favoring aggressive tumor biology. These findings remain significant in multivariate modeling accounting for radiation timing, dose, and fractionation schedules. Notably, neoadjuvant radiotherapy for the primary tumor demonstrated stronger negative prognostic impact than adjuvant approaches. These relationships have important implications for primary rectal cancer management decisions, as treatment approaches potentially influence salvage options for future recurrences. Emerging evidence suggests that alternative primary management strategies preserving radiation as a salvage option may warrant consideration in selected cases after accounting for these documented prognostic relationships.
Document 2 (Title: Pharmacological Management of Male Lower Urinary Tract Symptoms): Benign prostatic hyperplasia (BPH) represents a common condition affecting more than 50% of men over age 60, with progressive prevalence increasing with advancing age. The condition leads to bothersome lower urinary tract symptoms through both static (enlargement-related) and dynamic (tone-related) mechanisms of bladder outlet obstruction. Contemporary pharmacological management targets these distinct pathophysiological components with several medication classes. Alpha-1 adrenergic receptor antagonists act on the dynamic component by blocking sympathetic stimulation of smooth muscle within the prostate and bladder neck, thereby reducing urethral resistance without affecting prostate size. These agents are classified by receptor selectivity and pharmacokinetic properties. Tamsulosin demonstrates preferential affinity for alpha-1A receptors predominantly expressed in prostatic tissue, providing rapid symptom relief with minimal effects on vascular alpha-1B receptors, thereby reducing cardiovascular adverse effects such as orthostatic hypotension. This selective receptor profile makes tamsulosin particularly suitable for elderly patients and those with concurrent cardiovascular conditions. Alternative agents with different mechanisms include 5-alpha reductase inhibitors (finasteride, dutasteride), which address the static component by preventing conversion of testosterone to dihydrotestosterone, thereby reducing prostate volume over 3-6 months. Anticholinergic agents such as oxybutynin target bladder overactivity rather than outlet obstruction, but carry risk of urinary retention in men with significant BPH. Phosphodiesterase-5 inhibitors improve BPH symptoms through mechanisms involving nitric oxide pathways. Vasopressors like midodrine, indicated for orthostatic hypotension, have no role in BPH management and may worsen urinary symptoms through increased smooth muscle tone.
Document 3 (Title: Gastric Restrictive Procedures): 1. Vertical-Banded Gastroplasty (CPT code 43842) Vertical-banded gastroplasty was formerly one of the most common gastric restrictive procedures performed in the United States but has now been replaced by other restrictive procedures due to high rates of revisions and reoperations. In this procedure, the stomach is segmented along its vertical axis. To create a durable reinforced and rate-limiting stoma at the distal end of the pouch, a plug of stomach is removed, and a propylene collar is placed through this hole and then stapled to itself. Because the normal flow of food is preserved, metabolic complications are uncommon. Complications include esophageal reflux, dilation, or obstruction of the stoma, with the latter two requiring reoperation. Dilation of the stoma is a common reason for weight regain. Vertical-banded gastroplasty may be performed using an open or laparoscopic approach. 2. Adjustable Gastric Banding (CPT code 43770) Adjustable gastric banding involves placing a gastric band around the exterior of the stomach. The band is attached to a reservoir that is implanted subcutaneously in the rectus sheath. Injecting the reservoir with saline will alter the diameter of the gastric band; therefore, the rate-limiting stoma in the stomach can be progressively narrowed to induce greater weight loss, or expanded if complications develop. Because the stomach is not entered, the surgery and any revisions, if necessary, are relatively simple. Complications include slippage of the external band or band erosion through the gastric wall. Currently, two such devices are approved by the US Food and Drug Administration (FDA) for marketing in the United States. The first to receive FDA approval was the LapBand (Apollo Endosurgery). The labeled indications for Lap Band devices are as follows: "The Lap-Band system is indicated for use in weight reduction for severely obese patients with a body mass index (BMI) of at least 40 or a BMI of at least 35 with one or more severe comorbid conditions, or those who are 100 lbs or more over their estimated ideal weight according to the 1983 Metropolitan Life Insurance Tables (use the midpoint for medium frame). It is indicated for use only in severely obese adult patients who have failed more conservative weight-reduction alternatives, such as supervised diet, exercise and behavior modification programs. Patients who elect to have this surgery must make the commitment to accept significant changes in their eating habits for the rest of their lives." In 2011, FDA-labelled indications for the LAP-BAND were expanded to include patients with a BMI from 30 to 34 with at least 1 obesity-related comorbid condition. The second adjustable gastric banding device was approved by the FDA through the Premarket Approval (PMA) process in September 2007, the REALIZE model (Ethicon Endosurgery, Cincinnati, OH). Labeled indications for this device are as listed below: "The [REALIZE] device is indicated for weight reduction for morbidly obese patients and is indicated for individuals with a BMI of at least 40 kg/m2, or a BMI of at least 35 kg/m2 with one or more comorbid conditions. The band is indicated for use only in morbidly obese adult patients who have failed more conservative weight-reduction alternatives, such as supervised diet, exercise, and behavior modification programs." 3. Sleeve gastrectomy (CPT code 43775) A sleeve gastrectomy is an alternative approach to gastrectomy that can be performed on its own, or in combination with malabsorptive procedures (most commonly biliopancreatic diversion with duodenal switch). In this procedure, the greater curvature of the stomach is resected from the angle of His to the distal antrum, resulting in a stomach remnant shaped like a tube or sleeve. The pyloric sphincter is preserved, resulting in a more physiologic transit of food from the stomach to the duodenum, and avoiding the dumping syndrome (overly rapid transport of food through stomach into intestines) that is seen with distal gastrectomy. This procedure can be done by the open or laparoscopic technique. Some surgeons have proposed this as the first in a two-stage procedure for very high-risk patients. Weight loss following sleeve gastrectomy may improve a patient’s overall medical status, and thus reduce the risk of a subsequent more extensive malabsorptive procedure, such as biliopancreatic diversion.

Answer the following multiple-choice question.
Question: A 76-year-old African American man presents to his primary care provider complaining of urinary frequency. He wakes up 3-4 times per night to urinate while he previously only had to wake up once per night. He also complains of post-void dribbling and difficulty initiating a stream of urine. He denies any difficulty maintaining an erection. His past medical history is notable for non-alcoholic fatty liver disease, hypertension, hyperlipidemia, and gout. He takes aspirin, atorvastatin, enalapril, and allopurinol. His family history is notable for prostate cancer in his father and lung cancer in his mother. He has a 15-pack-year smoking history and drinks alcohol socially. On digital rectal exam, his prostate is enlarged, smooth, and non-tender. Which of the following medications is indicated in this patient?
Options:
A. Hydrochlorothiazide
B. Midodrine
C. Oxybutynin
D. Tamsulosin

Respond strictly in valid JSON format as follows:
{"answer_choice": "A"} ← if A is the answer
Output only the JSON object. Do not include any explanation, commentary, markdown, or extra text.